Drug utilization management programs cost physicians, patients, drug manufacturers and payors who impose these programs a collective $93.3 billion annually, according to a new report published in Health Affairs.
The authors, led by Scott Howell, the chief strategy officer of U.S. pharmaceuticals at Novartis, reviewed the literature and found that patients spend approximately $35.8 billion annually in drug cost sharing; physicians devote approximately $26.7 billion in administrative